Vous avez cherché: dolasetron (Anglais - Maltais)

dolasetron
dolasetron aloxi 100 milligramma 250 mikrogramma (n= 191)

dolasetron 100 milligrams (n= 191)
dolasetron 100 milligramma (n= 191)

percentage of patients a responding by treatment group and phase in the moderately emetogenic chemotherapy study versus dolasetron
7 perċentwali ta ’ pazjenti a li jirrispondu skond il- grupp tal- kura u l- fażi fl- istudju tabella 2: dwar il- kemoterapija moderatament emetoġenika kontra dolasetron

table 2: percentage of patients a responding by treatment group and phase in the moderately emetogenic chemotherapy study versus dolasetron
tabella 2: perċentwali ta’ pazjenti a li jirrispondu skont il-grupp tal-kura u l-fażi fl-istudju dwar il-kimoterapija moderatament emetoġenika mqabbla ma’ dolasetron

the effect of palonosetron on blood pressure, heart rate, and ecg parameters including qtc were comparable to ondansetron and dolasetron in cinv clinical studies.
l-effett ta’ palonosetron fuq il-pressjoni tad-demm, rata ta’ taħbit tal-qalb, u l-parametri tal-ecg li jinkludu qtc, kienu komparabbli għal ondansetron u dolasetron fl-istudji kliniċi cinv.

aloxi, given at two different doses, was compared with ondansetron and dolasetron (other medicines of the same type).
aloxi, mogħti f’żewġ dożaġġi differenti, tqabbel ma’ ondansetron u dolasetron (mediċini oħra tal-istess tip).

in clinical interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of ondansetron, granisetron, or hydrodolasetron (the active metabolite of dolasetron).
antagonisti ta '5- ht3 fi studji ta ’ interazzjonijiet kliniċi, aprepitant ma kellux effetti klinikament importanti fuq il- farmakokinetiċi ta ’ ondansetron, granisetron, jew hydrodolasetron (il- metabolit attiv ta ’ dolasetron).

in two randomised, double-blind studies with a total of 1,132 patients receiving moderately emetogenic chemotherapy that included cisplatin ≤ 50 mg/ m2, carboplatin, cyclophosphamide ≤ 1,500 mg/ m2 and doxorubicin > 25 mg/ m2, palonosetron 250 micrograms and 750 micrograms were compared with ondansetron 32 mg (half-life 4 hours) or dolasetron 100 mg (half-life 7.3 hours) administered intravenously on day 1, without dexamethasone.
f’ żewġ studji randomised, double- blind b’ total ta ’ 1, 132 pazjent li kienu qed jirċievu kemoterapija moderatament emetoġenika li kienet tinkludi cisplatin ≤ 50 mg/ m2, carboplatin, cyclophosphamide ≤ 1, 500 mg/ m2 u doxorubicin > 25 mg/ m2, palonosetron 250 mikrogramma u 750 mikrogramma, kienu mqabbla ma ’ ondansetron 32 mg (half- life ta ’ 4 sigħat) jew dolasetron 100 mg (half- life ta ’ 7. 3 sigħat) li ngħata minn ġol- vina f’ jum 1, mingħajr dexamethasone.